drugset
drugset / Trial / NCT03122444

Imipramine on ER+ve and Triple Negative Breast Cancer

NCT03122444 ↗

Phase 0 Completed 17 enrolled The University of Texas Health Science Center at San Antonio
NaSingle-groupOpen-labelTreatment

Summary

Comparing changes in biomarkers from a diagnostic core needle biopsy to surgical pathology specimen or repeat core needle biopsy.

Timeline

Start
2019-07-05
Primary completion
2022-03-01
Completion
2022-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Imipramine Small molecule 200 mg —

Indications

breast cancer